R-PA combined with butylphthalide soft capsules treatment improve the clinical prognosis in patient with acute progressive MCA cerebral ischemic stroke
-
摘要:
目的研究瑞替普酶(R-PA)联合丁苯肽胶囊在治疗进展性大脑中动脉急性缺血性脑卒中患者临床预后改善情况。 方法通过倾向性匹配法选取2015年1月1日~2017年5月31日在我科接受治疗的急性进展性大脑中动脉缺血性脑卒中患者87例,根据治疗方法不同分为两组:观察组44例,采用R-PA联合丁苯肽胶囊进行治疗;对照组43例,采用阿替普酶(rt-PA)联合丁苯肽胶囊进行治疗,其他治疗及康复两组患者保持一致。比较评价两组患者不同阶段的近期临床预后(NIHSS评分)和远期临床预后(GOS和ADL评分)情况。 结果观察组和对照组患者在性别构成、平均年龄、发病距开始治疗时间、脑梗死范围、入院时GCS评分等病情信息的差异均无统计学意义(P>0.05),具有较好的一致性;观察组和对照组患者在溶栓治疗后2 h、24 h、7 d 3个时间点的神经功能缺失情况差异无统计学意义(P>0.05),但是在第1月时观察组组患者的NIHSS评分均值更低,差异有统计学意义(P<0.05);观察组较对照组在第3、6、9月时GOS、ADL评分均更高,在第3月时差异无统计学意义(P>0.05),在第6、9月时差异有统计学意义(P<0.05)。以GOS评分在4分以上、ADL评分在75分以上为临床预后恢复良好,两组临床预后良好率差异虽无统计学意义(P>0.05),但观察组较对照组良好率更高,GOS评分两组良好率分别为70.45%、53.49%,ADL评分两组良好率分别为70.45%、60.47%。 结论R-PA联合丁苯肽相比较rt-PA联合丁苯肽治疗急性进展性大脑中动脉缺血性脑卒中患者的远期临床预后更好,作为rt-PA的衍生物,R-PA在急性进展性大脑中动脉缺血性脑卒中的治疗表现出一定的治疗优势。 -
关键词:
- 大脑中动脉缺血性脑卒中 /
- 瑞替普酶 /
- 临床预后
Abstract:ObjectiveTo explore the clinical prognosis after R-PA combined with Butylphthalide soft capsules treating patient with acute progressive MCA cerebral ischemic stroke. MethodA total of 87 cases with acute progressive MCA cerebral ischemic stroke from January 1st 2015 to May 31st 2015 were selected via orientation matching. The patients were divided into two groups based on different therapy method. 44 cases in observation group (R-PA group) were performed with R-PA combined with Butylphthalide soft capsules. The other 43 cases in control group (rt-PA group) received rt-PA combined with Butylphthalide soft capsules. The recent clinical prognosis were compared and evaluated by NIHSS scale and forward clinical prognosis by GOS and ADL scale. ResultsThe gender composition, age, the time from onset to receiving treatment, infarct area, and GCS at admission between two groups had no significant difference (P>0.05). There is no difference of NIHSS score between R-PA group and rt-PA group at 2th hour, 24th hour, and 7th day (P>0.05). The difference of NIHSS score between R-PA group and rt-PA group at 1th month was significant(P<0.05). It was lower in R-PA group. The GOS and ADL score were higher in R-PA group than that in rt-PA group at 3th, 6th, 9th month. There was no difference at 3th month (P>0.05), but had a significant difference at 6th, 9th month (P<0.05). GOS score above 4 and ADL score above 75 were considered as favorable prognosis. Although there was no significant difference between in R-PA group and rt-PA group, the favorable prognosis rate was higher in R-PA group than rt-PA group (GOS: 70.45%、53.49%; ADL: 70.45%、60.47%, respectively). ConclusionR-PA combined with Butylphthalide soft capsules treating patient with acute progressive MCA cerebral ischemic stroke has a better forward clinical prognosis than rt-PA combined with Butylphthalide soft capsules. As the rt-PA’s derivate, R-PA is valuable in treating acute progressive MCA cerebral ischemic stroke. -
Key words:
- MCA cerebral ischemic stroke /
- R-PA /
- Clinical prognosis
-
表 1 观察组和对照组患者一般资料及病情的比较
指标 分组 F /χ2 P 观察组(n=44) 对照组(n=43) 性别(n, 男/女) 23/21 19/24 0.570 0.450 年龄(Mean±SD,岁) 50.41±7.13 49.33±7.12 0.710 0.480 发病距开始治疗时间(Mean±SD,min) 184.18±39.35 173.86±37.18 1.257 0.212 脑梗死范围(Mean±SD,cm3) 68.75±10.15 69.88±9.73 0.532 0.596 入院时GCS评分(Mean±SD) 9.07±1.40 8.79±1.23 0.981 0.329 表 2 观察组和对照组患者NIHSS评分比较(Mean±SD)
溶栓治疗后时间 观察组(n=44) 对照组(n=43) t P 溶栓后2 h 23.70±4.93 24.35±5.38 0.583 0.561 溶栓后24 h 21.07±3.68 21.95±5.04 0.937 0.351 溶栓后7 d 15.93±2.54 16.72±2.05 1.593 0.115 溶栓后1月 12.14±4.41 13.98±3.45 2.165 0.033 表 3 观察组和对照组患者GOS评分比较(Mean±SD)
时间 观察组(n=44) 对照组(n=43) U/χ2 P 第3月 2.80±0.59 2.63±0.58 810.50 0.118 第6月 3.25±0.69 2.98±0.46 718.00 0.024 第9月 3.73±0.59 3.34±0.76 727.00 0.033 恢复良好率(%) 70.45(31/44) 53.49(23/43) 2.659 0.103 GOS>4分时认为临床结局为恢复良好. 表 4 观察组和对照组患者ADL评分比较(Mean±SD)
时间 观察组(n=44) 对照组(n=43) U/χ2 P 第3月 51.36±7.80 47.33±8.41 735.00 0.067 第6月 66.36±5.21 63.72±4.51 714.00 0.039 第9月 75.11±4.51 73.02±3.30 707.00 0.028 恢复良好率(%) 70.45(31/44) 60.47(26/43) 0.961 0.327 ADL>75分认为患者的日常生活能力恢复良好. -
[1] 刘建峰, 侯 凯, 李 辉, 等. 急诊动脉内溶栓再通及经皮腔内血管成形支架植入术治疗急性大脑中动脉闭塞疗效观察[J]. 中国全科医学, 2013, 16(42): 4325-8. [2] 陈效琴, 赵 诤, 邓有琦, 等. 急性缺血性脑卒中溶栓治疗进展[J]. 中国现代药物应用, 2016, 10(15): 286-8. [3] 袁长虹, 吴晓宇, 陈长春, 等. 小剂量阿替普酶治疗急性缺血性卒中的有效性和安全性: 与标准计量阿替普酶的比较[J]. 国际脑血管病杂志, 2019, 27(1): 12-6. [4] 鲍 宇, 李国忠. 阿替普酶与尿激酶治疗急性脑梗死疗效的比较研究[J]. 中风与神经疾病杂志, 2016, 33(7): 633-5. [5] 刘馨允, 张 优, 张 华, 等. 瑞替普酶与尿激酶对急性心肌梗死患者院内治疗有效性及安全性的多中心随机对照研究[J]. 中国动脉硬化杂志, 2016, 24(11): 1138-42. [6] 高 峰, 乔 梵. 尿激酶和瑞替普酶溶栓治疗急性脑梗死的疗效观察[J]. 中国中西医结合急救杂志, 2018, 25(5): 499-502. doi: 10.3969/j.issn.1008-9691.2018.05.012 [7] 陈会会, 尤东方, 酒 励, 等. 倾向性评分法和马氏距离法在匹配中的比较与应用[J]. 中国卫生统计, 2017, 34(6): 857-60, 865. [8] Jeyaseelan RD, Vargo MM, Chae J. National institutes of health stroke scale (NIHSS) as an early predictor of poststroke dysphagia[J]. PM R, 2015, 7(6): 593-8. doi: 10.1016/j.pmrj.2014.12.007 [9] 成 静. 缺血性脑卒中患者凝血功能与GCS、GOS评分的关系[J]. 中外医疗, 2014, 33(1): 59-60. [10] Ranner M, Guidetti S, Von Koch L, et al. Experiences of participating in a client-centred ADL intervention after stroke[J]. Disabil Rehabil, 2018, 22(1): 1-9. [11] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病组. 中国重症脑血管病管理共识[J]. 中华神经科杂志, 2016, 49(3): 192-202. doi: 10.3760/cma.j.issn.1006-7876.2016.03.004 [12] 任燕龙, 陈立颖, 康铁朵, 等. 脑卒中高风险人群高血压情况分析[J]. 临床神经病学杂志, 2018, 31(1): 23-5. doi: 10.3969/j.issn.1004-1648.2018.01.008 [13] 吐 亚, 张 天, 李桂花. 脑卒中患者急救医疗服务流程现状及临床研究[J]. 中国急救复苏与灾害医学杂志, 2018, 13(6): 527-9. doi: 10.3969/j.issn.1673-6966.2018.06.010 [14] 李 新, 王纪佐. 脑卒中亚型的新分类[J]. 中华神经科杂志, 2010, 43(8): 593-605. doi: 10.3760/cma.j.issn.1006-7876.2010.08.022 [15] Sanak D, Kecher M, Venerka T, et al. The safety and efficacy of bridging full-dose IV-IA thrombolysis in acute ischemic stroke patients with MCA occlusion: a comparison with IV thrombolysis alone[J]. Biomed Pap Med, 2014, 158(3): 391-6. doi: 10.5507/bp.2013.003 [16] 马 蓉. 急性脑卒中治疗的研究进展[J]. 重庆医学, 2019, 48(6): 1010-3. doi: 10.3969/j.issn.1671-8348.2019.06.029 [17] 娄一萍, 张圣, 严慎强, 等. 心房颤动对不同时间窗内急性缺血性脑卒中患者静脉溶栓结局的影响[J]. 中华神经科杂志, 2015, 48(8): 661-7. doi: 10.3760/cma.j.issn.1006-7876.2015.08.007 [18] 林 冠, 王翔宇, 周 丽, 等. 静脉溶栓治疗80岁以上急性缺血性脑卒中患者的疗效和安全性的进展[J]. 中国社区医师, 2019, 35(3): 11-2. doi: 10.3969/j.issn.1007-614x.2019.03.004 [19] 田 野, 张陈匀, 吴 曼, 等. 瑞替普酶在急性心肌梗死患者溶栓治疗中的疗效与安全性[J]. 中国老年学杂志, 2015, 27(9): 2535-6. doi: 10.3969/j.issn.1005-9202.2015.09.110 [20] Szabo S, Etzel D, Walter T, et al. Abciximab combined with half-dose reteplase has beneficial effects on inflammatory myocardial response in patients with myocardial infarction[J]. Blood Coagul Fibrinoly, 2009, 20(2): 129-33. doi: 10.1097/MBC.0b013e3283255368 [21] 高 峰, 刘亦华, 王旭磊, 等. 瑞替普酶治疗不同时间窗急性缺血性脑卒中的疗效评价[J]. 中华危重病急救医学, 2016, 28(11): 1029-31. doi: 10.3760/cma.j.issn.2095-4352.2016.11.018
计量
- 文章访问数: 809
- HTML全文浏览量: 243
- PDF下载量: 6
- 被引次数: 0